Anti-RIPK1 inhibitor - Bristol-Myers Squibb
Latest Information Update: 05 Oct 2023
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action RIPK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 05 Oct 2023 Discontinued - Phase-I for Autoimmune disorders in USA (unspecified route) (Bristol-Myers Squibb pipeline, October 2023)
- 01 Aug 2022 Phase-I clinical trials in Autoimmune disorders in USA (unspecified route) before August 2022 (Bristol-Myers Squibb pipeline, August 2022)
- 31 Jul 2022 Preclinical trials in Autoimmune disorders in USA (unspecified route) before August 2022